At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERAS Erasca, Inc.
Market Closed 06-14 16:00:00 EDT
2.17
-0.01
-0.46%
盘后2.17
+0.000.00%
19:53 EDT
High2.24
Low2.15
Vol672.20K
Open2.16
D1 Closing2.18
Amplitude4.13%
Mkt Cap591.48M
Tradable Cap251.72M
Total Shares272.57M
T/O1.46M
T/O Rate0.58%
Tradable Shares116.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.